Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients (RACHEL)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00931320
First received: June 30, 2009
Last updated: October 23, 2009
Last verified: October 2009

June 30, 2009
October 23, 2009
July 2009
Not Provided
Evaluate current LDL/HDL ratio in Korean patients (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking /Baseline : no limitation. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00931320 on ClinicalTrials.gov Archive Site
Evaluate difference of LDL/HDL ratio among different statins & dosages (between baseline & after treatment) [ Time Frame: After Treatment : at least 4 weeks before statin taking / Baseline : no limitation. ] [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients
Investigation Into the RAtio of LDL-CHolestEroL to HDL-Cholesterol Improvement After Statin Treatment in Korean Patients

An observational, non-interventional, multi-centre study to provide further information on the ratio of LDL-C to HDL-C improvement after statin treatment in Korean patients group.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Who have at least made 1 visit to the outpatient clinic within previous 6 months .

Dyslipidemias
Not Provided
3000 patients
Who have at least made 1 visit to the outpatient clinic within previous 6 months .
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
3000
September 2009
Not Provided

Inclusion Criteria:

  • Subjects who are taking lipid-lowering medication after diagnosed as dyslipidaemia
  • Subjects who have at least made 1 visit to the outpatient clinic within previous 6 months
  • Subjects who have records of both LDL-C and HDL-C before & after statin treatment (at least four weeks after statin taking)

Exclusion Criteria:

  • Subjects who are unwilling or unable to provide their examination and lab result of medical chart.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00931320
NIS-CKR-DUM-2009/3
No
Hyunah Caroline, Choi / CV TA Physician, AstraZeneca Pharmaceuticals
AstraZeneca
Not Provided
Study Director: Hyunah Caroline Choi AstraZeneca Korea
AstraZeneca
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP